Skip to main content
SpringerLink
Log in

Modification of tumor cells by a low dose of Newcastle disease virus

II. Augmented tumor-specific T cell response as a result of CD4+ and CD8+ immune T cell cooperation

  • Original Articles
  • Published:
Cancer Immunology, Immunotherapy Aims and scope Submit manuscript

Summary

Augmented tumor-specific T cell responses were observed against the high metastatic murine lymphoma variant ESb when using as immunogen ESb tumor cells that had been modified by infection with a low dose of Newcastle disease virus (NDV). Such virus-modified inactivated tumor cells (ESb-NDV) were potent tumor vaccines when applied postoperatively for active specific immunotherapy of ESb metastases. We demonstrate here that immune spleen cells from mice immunized with ESb-NDV contain enhanced immune capacity in both the CD4+, CD8− and the CD4−, CD8+ T cell compartments to mount a secondary-tumor-specific cytotoxic T cell response in comparison with immune cells from mice immunized with ESb. ESb-NDV immune CD4+, CD8− helper T cells also produced more interleukin 2 after antigen stimulation than the corresponding ESb immune cells. There was no participation of either CD4+ or CD8+ virus-specific cells in the augmented response. The specificity of the T cells for the tumor-associated antigen remaind unchanged. Thus, there is the paradox that the virus-mediated augmentation of the tumor-specific T cell response in this system involves increased T helper activity but does not involve the recognition of viral epitopes as potential new helper determinants.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Abbreviations

CTL:

cytolytic T lymphocytes

IL-2:

interleukin 2

rIL-2:

recombinant IL-2

mAb:

monoclonal antibody

NDV:

Newcastle disease virus

SSC:

syngeneic spleen cell

References

  1. Altevogt P, Leidig S, Heckl-Oestreicher B (1984) Resistance of metastatic tumor variants to tumor specific cytotoxic T lymphocytes not due to defects in expression of restricting MHC molecules. Cancer Res 44:5305

    Google Scholar 

  2. Austin FC, Boone CW (1979) Virus augmentation of the antigenicity of tumor cell extracts. Adv Cancer Res 30:301

    Google Scholar 

  3. Bosslet K, Schirrmacher V, Shantz G (1979) Tumor metastases and cell-mediated immunity in a model system in DBA/2 mice: VI. Similar specificity patterns of protective anti-tumor immunity in vivo and of cytolytic T cells in vitro. Int J Cancer 24:303

    Google Scholar 

  4. Ceredig R, Lowenthal JW, Nabholz M, MacDonald HR (1985) Expression of interleukin-2 receptors as a differention marker on intrathymic stem cells. Nature 314:98

    Google Scholar 

  5. Cobbold SP, Nash AJ, Prospero TD, Waldmann H (1984) Therapy with monoclonal antibodies by elimination of T-cell subsets in vivo. Nature 312:1698

    Google Scholar 

  6. Dialynas DP, Quan ZS, Wall KA, Pierres A, Quintans J, Loken MR, Pierres M, Fitch FW (1983) Characterization of the murine T cell surface molecule, designated L3T4, identified by monoclonal antibody GK1.5: similarity to the human Leu-3/T4 molecule. J Immunol 131:2445

    Google Scholar 

  7. Forni G, Giovarelli M (1986) Strategies for cell-mediated immunotherapy of cancer: killing or help? Immunol Today 7:202

    Google Scholar 

  8. Fujiwara H, Yoshioka T, Shima J, Kozugi A, Itoh K, Hamaoka T (1986) Helper T cells against tumor associated antigens (TAA): preferential induction of helper T cell activities involved in anti-TAA cytotoxic T lymphocyte and antibody responses. J Immunol 136:2715

    Google Scholar 

  9. Gillis S, Frem MM, Ou W, Smith KA (1978) T cell growth factor: parameters of production and a quantitative microassay for activity. J Immunol 120:2027

    Google Scholar 

  10. Giovarelli M, Santoni A, Forni G (1985) Alloantigen-activated lymphocytes from mice bearing a spontaneous “nonimmunogeneic” adenocarcinoma inhibit its growth in vivo by recruiting host immunoreactivity. J Immunol 133:3596

    Google Scholar 

  11. Heeg K, Reimann J, Kabelitz D, Hardt C, Wagner H (1985) A rapid colorimetric assay for the determination of IL-2 producing helper cell frequencies. J Immunol Methods 77:237

    Google Scholar 

  12. Heicappell R, Schirrmacher V, von Hoegen P, Ahlert T, Appelhans B (1986) Prevention of metastatic spread by postoperative immunotherapie with virally modified autologous tumor cells. I. Parameters for optimal therapeutic effects. Int J Cancer 37:569

    Google Scholar 

  13. Hoegen P von, Altevogt P, Schirrmacher V (1987) New antigens present on tumor cells can cause immune rejection without influencing the frequency of tumor specific cytolytic T cells. 1987. Cellular Immunol 109:338

    Google Scholar 

  14. Hoegen P von, Weber E, Schirrmacher V (1988) Modification of tumor cells by a low dose of Newcastle disease virus: I. Augmentation of the tumor cell specific T cell response in the absence of an anti-viral response. Eur J Immunol 18:1159–1166

    Google Scholar 

  15. Kobayashi H (1979) Viral xenogenisation of intact tumor cells. Adv Cancer Res 30:279

    Google Scholar 

  16. Kobayashi H (1986) The biological modification of tumor cells as a means of inducing their regression: an overview. J Biol Resp Mod 5:1

    Google Scholar 

  17. Mosmann T (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65:55

    Article  PubMed  Google Scholar 

  18. Reddehase M, Suessmuth W, Moyers C, Falk W, Droege W (1982) Interleukin 2 is not sufficient as helper component for the activation of cytotoxic T lymphocytes but synergizes with a late helper effect that is provided by I region-incompatible stimulator cells. J Immunol 128:61

    Google Scholar 

  19. Russel PH (1984) Newcastle disease virus: the effect of monoclonal antibody in the overlay on virus penetration and the immunoselection of variants. J Gen Virol 65:795

    Google Scholar 

  20. Sarmiento M, Glasbrook AL, Fitch FW (1980) IgG or IgM monoclonal antibodies reactive with different determinants of the molecular complex bearing Lyt 2 antigen block T cell mediated cytolysis in the absence of complement. J Immunol 125:2665

    Google Scholar 

  21. Schild H-J (1987) The role of CD4+ T helper cells in the induction of killer cells against a syngeneic tumor. Diploma thesis, Heidelberg

  22. Schild H-J, Kyewski B, Hoegen P von, Schirrmacher V (1987) CD4+ helper T cells are required for resistence to a highly metastatic murine tumor. Eur J Immunol 17:1863

    Google Scholar 

  23. Schirrmacher V (1986) Postoperative activation of tumor-specific T cells as a means to achieve immune control of minimal residual disease. In: Fortner JG, Rhoads JE (eds) Accomplishments in cancer research 1986. General Motors Cancer Research Foundation, p 218–232

  24. Schirrmacher V, Ahlert T, Heicappell R, Appelhans B, Hoegen P von (1986) Successful application of non-oncogenic viruses for antimetastatic cancer immunotherapy. Cancer Rev 5:19–49

    Google Scholar 

  25. Schirrmacher V, Hoegen P von, Heicappell R, Altevogt P (1987) Modulations of tumor cell immunogenicity leading to increased T cell reactivity and decreased metastases formation. In: Herbermann RB, Wiltrout R, Gorelik E (eds) Immune responses to metastates. II. CRC Press, Boca Raton, p 1–11

    Google Scholar 

  26. Schirrmacher V, Heicappell R (1987) Prevention of metastatic spread by postoperative immunotherapy with virally modified autologous tumor cells. II. Establishment of specific systemic immunity. Clin Exp Met 5, 147–156

    Google Scholar 

  27. Schirrmacher V, Hoegen P von, Heicappell R, Griesbach A, Altevogt P (1989) Prevention of metastatic spread by postoperative immunotherapy with virally modified autologous tumor cells. III. Postoperative activation of tumor specific CTLP from mice with metastases requires stimulation with the specific antigen plus additional signals. Inv Met (in press)

  28. Takai Y, Kosugi A, Yoshioka T, Tomita S, Fujiwara H, Hamaoka T (1985) T-T cell interaction in the induction of delayed-type hypersensitivity (DTH) responses: vaccinia virus-reactive helper T cell activity involved in enhanced in vivo induction of DTH responses and its application to augmentation of tumor-specific DTH responses. J Immunol 134:108

    Google Scholar 

  29. Yoshioka T, Fukuzawa M, Takei Y, Wakamiya N, Ueda S, Kato S, Fujiwara H, Hamaoka T (1986) The augmentation of tumor specific immunity by virus help: III. Enhanced generation of tumor-specific Lyt1+2− T cells is responsible for augmented tumor immunity in vivo. Cancer Immunol Immunother 21:193

    Google Scholar 

Download references

Author information

Author notes

  1. Hansjörg Schild

    Present address: Max-Planck-Institut für Biologie, Abteilung Immungenetik, Corrensstrasse 42, D-7400, Tübingen, FRG

Authors and Affiliations

  1. Institute for Immunology and Genetics, German Cancer Research Center, D-6900, Heidelberg, Federal Republic of Germany

    Hansjörg Schild, Paul von Hoegen & Volker Schirrmacher

Authors
  1. Hansjörg Schild
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Paul von Hoegen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Volker Schirrmacher
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Schild, H., von Hoegen, P. & Schirrmacher, V. Modification of tumor cells by a low dose of Newcastle disease virus. Cancer Immunol Immunother 28, 22–28 (1989). https://doi.org/10.1007/BF00205796

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00205796

Keywords

Search

Navigation